Certain women with advanced ovarian cancer whose tumors haven’t responded to at least 2 chemotherapy drugs have a new FDA-approved treatment option.
The agency gave the nod to rucaparib for treating ovarian tumors with harmful BRCA gene mutations. Marketed as Rubraca, the drug was approved along with a companion diagnostic test used to detect the mutations. The agency granted the drug accelerated approval, which is given to treatments for serious illnesses based on a surrogate end point likely to predict clinical benefit.
Voelker R. Ovarian Cancer Drug Approved. JAMA. 2017;317(5):466. doi:10.1001/jama.2017.0026
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: